Overview

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Determination of the relative bioavailability of 2 different formulations of a 5 mg linagliptin (BI 1356)/45 mg pioglitazone fixed dose combination (FDC) tablet, formulation C5 and formulation C8, compared with the mono-components linagliptin and pioglitazone administered together

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Linagliptin
Pioglitazone